Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Petros Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company focused on the development and commercialization of therapies for men’s health conditions. The company operates within the biopharmaceutical and men’s health therapeutics industries, with historical and ongoing emphasis on sexual health and dermatological indications. Its activities have primarily centered on developing prescription and over-the-counter pharmaceutical products rather than large-scale in‑house manufacturing.
Historically, Petros is best known for its role in the development of avanafil, a phosphodiesterase‑5 (PDE‑5) inhibitor for erectile dysfunction, which was commercialized as STENDRA® in the United States. While Petros no longer markets STENDRA® directly, the product established the company’s positioning in men’s sexual health. In subsequent years, Petros shifted its strategic focus toward new men’s health products, including treatments for androgenic alopecia. The company was incorporated in 2020 through the rebranding and restructuring of Metuchen Pharmaceuticals, Inc., following changes in ownership and strategic direction.
Business Operations
Petros Pharmaceuticals’ operations are organized around product development, regulatory advancement, and licensing or commercialization partnerships. The company’s primary business activities include clinical development, formulation optimization, intellectual property management, and pursuit of regulatory approvals. Revenue generation has historically relied on licensing arrangements, milestone payments, and, when applicable, product sales through partners rather than direct-to-market distribution.
The company’s most notable development-stage asset has been H100, a topical investigational product intended for the treatment of androgenic alopecia. Petros does not maintain large manufacturing facilities and instead relies on third-party contract research organizations and manufacturers for clinical trials, formulation, and production. Public disclosures indicate limited international operations, with activities largely concentrated in the United States. Information regarding current recurring revenue streams is limited, and data inconclusive based on available public sources reflects ongoing operational restructuring.
Strategic Position & Investments
Strategically, Petros Pharmaceuticals has sought to reposition itself as a focused men’s health developer by advancing late-stage or differentiated therapeutic candidates and leveraging prior regulatory experience. Growth initiatives have centered on progressing H100 through clinical and regulatory pathways and exploring strategic alternatives such as partnerships, licensing, or asset sales to maximize shareholder value.
The company previously divested or licensed rights related to STENDRA®, transferring U.S. commercialization rights to Metuchen Pharmaceuticals, LLC, while retaining certain economic interests. Public filings indicate that Petros has evaluated strategic transactions, cost-reduction initiatives, and balance sheet restructuring. Disclosures also reflect that the company has faced financial constraints and restructuring activity; however, the precise status and long-term impact of these actions are data inconclusive based on available public sources.
Geographic Footprint
Petros Pharmaceuticals is headquartered in the United States, with its principal executive offices historically located in New York. The company’s operational footprint is primarily domestic, reflecting its focus on U.S. regulatory approvals and U.S.-based development programs.
International exposure has been limited and largely indirect, consisting of intellectual property rights, licensing arrangements, or potential future commercialization opportunities outside the U.S. The company does not report significant owned infrastructure or personnel across Europe, Asia, or other global regions, and its international influence is primarily strategic rather than operational.
Leadership & Governance
Petros Pharmaceuticals is led by a management team with experience in pharmaceuticals, corporate finance, and regulated product development. Leadership has emphasized capital discipline, portfolio focus, and strategic optionality in response to market and financial conditions. Governance is overseen by a board of directors responsible for strategic oversight, restructuring decisions, and shareholder interests.
Key executives reported in recent public disclosures include:
- Fady Boctor – Chief Executive Officer and Chairman of the Board
- Jose Cordon – Chief Financial Officer
- Barry J. Kogan – Chief Legal Officer and Corporate Secretary
Management and board composition have changed over time, reflecting the company’s evolving strategy and financial position. Where conflicting executive information appears across filings and market data, data inconclusive based on available public sources applies.